We firstly applied drug target MR to investigate the association of genetically proxied lipid-lowering drug targets (HMGCR, PCSK9, and NPC1L1) with overall prostate cancer risk (Fig 2 and S6 Table). This evidence concerns the gene NPC1L1 and prostate carcinoma.